Posted by Michael Wonder on 07 Dec 2021
FDA approves Octapharma’s Cutaquig 16.5% for paediatric PI patients, providing flexible treatment options
7 December 2021 - Families, providers can utilise flexible infusion schedule to meet patient needs.
Octapharma USA today announced the U.S. Food & Drug Administration has approved Cutaquig [immune globulin, subcutaneous (human)-hipp, 16.5% solution] for the treatment of paediatric patients age 2 and older with primary humoral immunodeficiency.
The FDA previously approved Cutaquig for adults with primary humoral immunodeficiency.
